Here's Why Idera Pharmaceuticals, Inc. Is Surging Today
Shares of Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotech advancing novel therapies for skin-related diseases, are getting a bump after the company presented trial results at the annual European Society for Medical Oncology conference on Sunday. The stock is up about 16.9% as of 12:05 p.m. EDT on Monday.
On Sunday, Idera Pharmaceuticals presented final results from the dose-selection stage of a phase 1/2 trial investigating its melanoma candidate IMO-2125 in combination with Yervoy from Bristol-Myers Squibb. All but one of 18 patients enrolled in the exploratory trial experienced disease progression after treatment with increasingly popular PD-1 inhibitors Opdivo or Keytruda, and nine were treated with the dosage that will be used in the phase 2 stage of the trial.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Aktie
Mit 22 Buy-Einschätzungen und nur 3 Sell-Einschätzungen ist Bristol-Myers Squibb einer der Lieblinge unserere Community.
Ein leichtes Potenzial nach oben für Bristol-Myers Squibb mit einem Kursziel von 60 € gegenüber dem aktuellen Kurs von 55.48 €.
